BRAIN Biotech AG
XETRA: BNN.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adriaan Moelker
- Employees
- 296
- Headquarters
- Zwingenberg, Germany
- IPO year
- 2016
- Market cap
- €69.3M
- Website
- https://www.brain-biotech.com
Loading BNN…
Loading profile data…Frequently asked questions about BNN
What does BRAIN Biotech AG (BNN.DE) do?
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natur...
Where does BNN.DE trade?
BRAIN Biotech AG (BNN.DE) trades on the Deutsche Börse.
What sector is BNN.DE in?
BRAIN Biotech AG (BNN.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BRAIN Biotech AG?
Adriaan Moelker is the chief executive officer of BRAIN Biotech AG (BNN.DE).
Where is BRAIN Biotech AG headquartered?
BRAIN Biotech AG is headquartered in Germany.
Does BNN.DE pay a dividend?
BRAIN Biotech AG (BNN.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BNN.DE go public?
BRAIN Biotech AG (BNN.DE) completed its initial public offering in 2016.